Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX versus CEFOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX versus CEFOBID.
CEFIZOX vs CEFOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
None Documented
None Documented
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
2 hours (prolonged in hepatic impairment and neonates).
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic